|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Participants in the bottom 30% (ie, SBP decreased on standing) were significantly older, had a greater prevalence of hypertension and peripheral vascular disease, had higher values of SBP, and had more cigarette-years of smoking.
|
10334798 |
1999 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Multivariable logistic models showed that the two polymorphisms were significantly associated with severe hypertension (SBP > or = 160 mm Hg or DBP > or = 100 mm Hg regardless of medication use), with an OR of 0.6(95% confidence interval [CI]: 0.4-0.98) for S482S vs. G482G and an OR of 1.9(95% CI: 1.2-3.0) for +2962G/G vs. +2962A/A, but not with regular hypertension (SBP > or = 140 mm Hg or DBP > or = 90 mm Hg or current use of antihypertensive medications), with an OR of 0.9(95% CI: 0.7-1.2) for S482S vs. G482G and an OR of 0.9(95% CI: 0.7-1.4) for +2962G/G vs. +2962A/A.
|
17971240 |
2007 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
We conducted GWAS for three BP traits [systolic and diastolic blood pressure (SBP and DBP); hypertension (HYP)] in the Kooperative Gesundheitsforschung in der Region Augsburg (KORA) S3 cohort (n = 1644) recruited from general population in Southern Germany.
|
19304780 |
2009 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
The genetic risk score, calculated as the sum of BP-increasing alleles of FGF5-rs16998073, CYP17A1-rs11191548, CYP17A1-rs1004467 and MTHFR-rs17367504, was significantly associated with increased SBP (1.16 mmHg/allele, P = 9.01E-5), DBP (0.51 mmHg/allele, P = 4.40E-4) and hypertension risk (OR = 1.22/allele, P = 2.74E-7).
|
20852445 |
2011 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
In contrast, in inactive group, two polymorphisms and genetic risk score were significantly associated with SBP (rs17249754: β = 1.26, 95% confidence interval (CI) 0.61-1.90, p < 0.001; rs1004467: β = 0.68, 95%CI 0.03-1.32, p = 0.039; genetic risk score: β = 1.54, 95%CI 0.74-2.33, p < 0.001); three polymorphisms and genetic risk score were significantly associated with hypertension (rs17249754: odds ratio (OR) = 1.27, 95%CI 1.08-1.49, p = 0.004; rs1378942: OR = 1.25, 95%CI 1.00-1.57, p = 0.050 (marginally significant); rs16998073: OR = 1.17, 95%CI 1.01-1.37, p = 0.044; genetic risk score: OR = 1.38, 95%CI 1.13-1.68, p = 0.001).
|
23102448 |
2012 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
We observed that the non-coding SNP rs2289277 was associated with TSLP mRNA abundance (P=0.04), as well as with SBP [systolic BP (blood pressure)] (P=0.004) and DBP (diastolic BP) (P=0.0003) in men when adjusting for age, waist circumference, smoking and medication treating hypertension.
|
22304237 |
2012 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
In the normal weight group, we did not observe any significant association of 6 SNPs and the genetic risk score (GRS) with SBP/DBP and hypertension (all P > 0.05).
|
23591986 |
2013 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
This exploratory study reports two plausible loci associated with SBP response to hydrochlorothiazide: TET2, an aldosterone-responsive mediator of αENaC gene transcription; and CSMD1, previously described as associated with hypertension in a case-control study.
|
25695618 |
2015 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
When stratified by the hypertension medication status, interaction effect was found only in individuals taking medication (P-interaction = 0.004 for SBP and 0.001 for DBP).
|
25304467 |
2015 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Thresholds for identifying ambulatory hypertension (daytime systolic BP [SBP]/diastolic BP [DBP] ≥135/85 mm Hg, 24-hour SBP/DBP ≥130/80 mm Hg, and nighttime SBP/DBP ≥120/70 mm Hg) have been derived from European, Asian, and South American populations.
|
28428231 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
In addition, we found that systolic pressure (SBP; 129.32 ± 14.86 mmHg, <i>p</i> = 0.041), body mass index (BMI; 22.54 ± 2.71, <i>p</i> = 0.046), and low-density lipoprotein (LDL; 3.09 ± 0.98 mmol/L, <i>p</i> = 0.048) in the subjects with PES were significantly higher than those measurements in the CN subjects (SBP; 122.06 ± 10.55 mmHg; BMI; 20.24 ± 2.13; LDL; 2.91 ± 0.76 mmol/L), and there was a significant negative correlation between an increased adult hypertension risk and a shorter LTL.
|
29085308 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
In 'fit' participants, the decline in SBP was 12.4 (95% confidence interval 11.9-13.0) mmHg/decade in those treated for hypertension and 8.5 (7.8-9.1) mmHg in those not treated.
|
28441696 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
ERA significantly reduced 24-h ambulatory blood pressure and sitting blood pressure in patients with hypertension [5 trials, 24-h SBP: WMD -7.65 (-8.95 to -6.36), 24-h DBP: WMD -5.92 (-7.50 to -4.33); 18 trials, SBP: WMD -6.12 (-7.87 to -4.36), DBP: WMD -3.81 (-4.82 to -2.80)].
|
27808564 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
The impact of DBP on the risk of developing hypertension compared with optimal BP (SBP <120 mm Hg and DBP <80 mm Hg) was significantly greater than that of SBP in subjects younger than 50 years (hazard ratios, 17.5 for isolated diastolic high-normal vs 10.5 for isolated systolic high-normal [P<.001]; 8.0 for isolated diastolic normal vs 4.1 for isolated systolic normal [P<.001]).
|
28444926 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Pre- and undiagnosed-hypertension was defined as systolic blood pressure/ diastolic blood pressure (SBP/DBP) of 120-139/80-89 mm Hg and SBP⩾140 mm Hg and/or DBP⩾90 mm Hg, respectively, in participants without a history of hypertension and use of antihypertensive medication.
|
27654328 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Urinary sodium (F [4,323] = 20.381; P < 0.0005; adjusted R<sup>2</sup> = 0.231) and sodium-to-potassium ratio (F[4,323] = 25.008; P < 0.0005; adjusted R<sup>2</sup> = 0.227) significantly predicted SBP after controlling for age, sex, BMI, and hypertension medication use.
|
27712964 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
MRI-derived subclinical HFF is associated with SBP and DBP as well as with hypertension in participants from the general population without history of cardiovascular disease.
|
28253218 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Asian people with hypertension: SBP: MD -7.75 mmHg (95% CI:-11,44 to -4.07; P < 0.0001) nine studies, 501 participants; DBP: MD -2.68 mmHg (95% CI: -4.21 to -1.15; P = 0.0006).
|
28391629 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Distinguishing trajectories allows identification of subgroups at risk of hypertension and cardiovascular disease later in life and in addition can inform the design of targeted interventions to attenuate high SBP and DBP trajectories over time and maintain normal trajectories.
|
28234673 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
One-in-three antihypertensive medication users had stage 2 hypertension (SBP ≥160/DBP ≥100 mmHg).
|
28545582 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Those who converted to normotension were younger, less obese, and had significantly lower baseline SBP, fasting glucose, cholesterol levels, and homeostasis model assessment insulin resistance compared with study participants who continued to have prehypertension or progressed to hypertension.
|
28169882 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
After 1 month, superior SBP (-3.1 mmHg, P = 0.02) and DBP (-2.8 mmHg, P < 0.001) reductions were observed with perindopril/indapamide/amlodipine, which were even more pronounced after excluding white-coat effect in the sustained hypertension population (-5.3/-3.7 mmHg).
|
28306636 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Familial presence of hypertension and/or obesity was significantly associated with SBP among adolescent females but not males.
|
28633388 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
In the EMPA-REG BP trial, empagliflozin significantly reduced systolic and diastolic blood pressure (SBP and DBP) compared with placebo at week 12 in patients with type 2 diabetes mellitus (T2DM) and hypertension.
|
28387058 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Orthostatic hypotension-related hospitalizations were predicted by age [per 1-year increase, hazard ratio 1.14, 95% confidence interval (CI): 1.12-1.16], smoking (hazard ratio 1.35, 95% CI: 1.12-1.64), diabetes (hazard ratio 1.50, 95% CI: 1.00-2.25), baseline orthostatic hypotension (hazard ratio 1.45, 95% CI: 1.05-1.98), in particular, by SBP fall at least 30 mmHg (hazard ratio 3.93, 95% CI: 2.14-7.23), whereas syncope hospitalizations by age (per 1-year increase, hazard ratio 1.09, 95% CI: 1.07-1.11), smoking (hazard ratio 1.27, 95% CI: 1.08-1.49), and hypertension (hazard ratio 1.42, 95% CI: 1.20-1.69).
|
28009704 |
2017 |